Clinical Trial

Antifungal Drugs in Pulmonary Mucormycosis

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 1, 2025 (before its estimated July 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of 5mg/kg/day combined with isavuconazole versus using AmBisome for the management of pulmonary mucormycosis
Trial Details
NCT Number NCT06756191
Lead Sponsor Bin Cao
Conditions Pulmonary Mucormycosis
Enrollment 312 participants
Start Date 2025-01-10
Primary Completion 2025-07-10 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-01